Trojan mast cells: repurposing allergy for targeted oncolytic delivery
Trends in Pharmacological Sciences · 2026
DOI: 10.1016/j.tips.2026.08.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Pharmacological Sciences, 2026. Verfasst von Mengqin Guo und 2 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecule…. Hauptthemen laut MEDLINE: Mast Cells, Neoplasms, Oncolytic Viruses, Oncolytic Virotherapy. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Oncolytic viruses hold immense therapeutic promise but face formidable systemic delivery barriers. A new study by Xu et al. engineered immunoglobulin E-sensitized mast cells to selectively ferry these viruses into tumors. Excitingly, antigen-triggered degranulation precisely releases the viral payload and reshapes the immune microenvironment, offering a highly modular delivery paradigm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, College of Pharmacy, Jinan Univer…
- School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Zitieren
APA
Guo, M., Wang, W., & Huang, Z. (2026). Trojan mast cells: repurposing allergy for targeted oncolytic delivery. Trends in Pharmacological Sciences. https://doi.org/10.1016/j.tips.2026.08.001
Vancouver
Guo M, Wang W, Huang Z. Trojan mast cells: repurposing allergy for targeted oncolytic delivery. Trends in Pharmacological Sciences. 2026. doi:10.1016/j.tips.2026.08.001
BibTeX
@article{Guo2026,
author = {Guo, Mengqin and Wang, Wenhao and Huang, Zhengwei},
title = {Trojan mast cells: repurposing allergy for targeted oncolytic delivery},
journal = {Trends in Pharmacological Sciences},
year = {2026},
doi = {10.1016/j.tips.2026.08.001}
}
EUVIMED